NeuroPace Inc

NeuroPace Inc (NPCE) priced its initial public offering on Apr 23, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $102M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $389.8M. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley, Wells Fargo and Leerink Partners.

NeuroPace Inc is a commercial-stage medical device company focused on epilepsy. Its RNS System monitors the brain's electrical activity and responds with small electrical pulses to prevent seizures, and it records brain data that clinicians can review in person or remotely.

Status

IPO

Ticker

NPCE

Exchange

Nasdaq Global Market

Priced

Apr 23, 2021

IPO price

$17.00

Price range

$15.00–$17.00

Raised

$102M

Market cap at IPO price

$389.8M

First filed

Mar 24, 2021

Underwriters

J.P. Morgan, Morgan Stanley, Wells Fargo and Leerink Partners

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.